Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BioStem Technologies, Inc. (OTC: BSEM).

Full DD Report for BSEM

You must become a subscriber to view this report.


Recent News from (OTC: BSEM)

BioStem Technologies Selects PCG Advisory Group for Investor Relations and Strategic Communications
Pompano Beach, FL, Oct. 17, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a global life sciences corporation providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine, ...
Source: GlobeNewswire
Date: October, 17 2018 08:00
BioStem launches four amniotic products; investors unmoved, shares down 9%
Ultra-thinly traded BioStem Technologies ( OTCPK:BSEM -8.5% ) is down on light volume on the heels of its announcement that subsidiary BioStem Life Sciences is rolling out four new placental-derived products for a range of indications. More news on: BioStem Technologies, Inc., Healthca...
Source: SeekingAlpha
Date: October, 01 2018 12:18
BioStem Life Sciences, Inc., Subsidiary of BioStem Technologies, Inc., Announces Entry into Market with Four Amniotic Products
Pompano Beach, FL, Oct. 01, 2018 (GLOBE NEWSWIRE) -- BioStem Life Sciences (“Life Sciences” or the “Company”), a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM), a Company focused on the development of the highest quality placental-based ...
Source: GlobeNewswire
Date: October, 01 2018 10:45
BioStem Technologies Inc. to Present at The MicroCap Conference on October 1st and 2nd in New York City at the Essex House
Pompano Beach, FL, Sept. 19, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine...
Source: GlobeNewswire
Date: September, 19 2018 09:00
Nesvik Pharmaceuticals, Inc., a Subsidiary of BioStem Technologies, Inc., Announces Engagement of The Gnomon Group for Pre-Investigational New Drug Application Strategy
Pompano Beach, FL, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Nesvik Pharmaceuticals, Inc., a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), focused on the development of novel reformulated pharmaceutical products tha...
Source: GlobeNewswire
Date: September, 17 2018 10:43
Nesvik Pharmaceuticals, Inc., Receives Updated U.S. FDA Establishment Registration in Light of New Product Development
Pompano Beach, FL, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Nesvik Pharmaceuticals, Inc., a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), focused on the development of novel reformulated pharmaceutical products that...
Source: GlobeNewswire
Date: August, 28 2018 10:10
BioStem Technologies, Inc. Completes 2016, 2017 Audit of Financial Statements
Pompano Beach, FL., Aug. 17, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM), a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine that exponentially improve, extend, and transform the qu...
Source: GlobeNewswire
Date: August, 17 2018 09:30
BioStem Technologies, Inc. Engages Maxim Group LLC For Strategic Advisory Services
Fort Lauderdale, FL, Aug. 15, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), (the “Company” or “BioStem Technologies”) a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regener...
Source: GlobeNewswire
Date: August, 15 2018 09:00
BioStem Technologies, Inc. (BSEM) Launches New Subsidiary to Engage in the Processing and Supply of Regenerative Tissue Products
Pompano Beach, FL, Aug. 09, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmac...
Source: GlobeNewswire
Date: August, 09 2018 09:00
BioStem Technologies Inc. Launches Expanded Shareholder Communications Initiative
Pompano Beach, FL, Aug. 08, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine ...
Source: GlobeNewswire
Date: August, 08 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-073.903.993.993.851,226
2018-12-063.903.903.903.90200
2018-12-053.554.004.003.081,881
2018-12-043.554.004.003.081,881
2018-12-033.53453.553.553.5345790

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-078911,22672.6754Short
2018-12-047991,88142.4774Short
2018-12-0369079087.3418Short
2018-11-301,1151,95257.1209Short
2018-11-29531531100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BSEM.


About BioStem Technologies, Inc. (OTC: BSEM)

Logo for BioStem Technologies, Inc. (OTC: BSEM)

BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drives shareholder value.

 

 

 

Current Management

  • Henry VanVurst / CEO, CoFounder
  • Andrew VanVurst / COO, CoFounder
  • Jason Matuszewski / CFO, President, CoFounder
  • Larry Jones / Chief Revenue Officer
  • Henry VanVurst / Chairman
  • Jason Matuszewski /
  • Dr. Jennie Sandqvist / Independent Director
  • Andrew VanVurst /
  • Robert Watson / Independent Director

Current Share Structure

  • Market Cap: $62,681,124 - 03/15/2018
  • Authorized: 975,000,000 - 02/15/2018
  • Issue and Outstanding: 7,439,013 - 01/31/2018
  • Float: 4,214,289 - 02/15/2018

 


Recent Filings from (OTC: BSEM)

Quarterly Report - Quarterly Disclosure Statement Q3 - 2017
Filing Type: Quarterly Report - Quarterly Disclosure Statement Q3 - 2017Filing Source: OTC Markets
Filing Date: November, 17 2017
Quarterly Report - Quarterly Financial Footnotes Q3 - 2017
Filing Type: Quarterly Report - Quarterly Financial Footnotes Q3 - 2017Filing Source: OTC Markets
Filing Date: November, 16 2017
Quarterly Report - Quarterly Financials Q3 2017
Filing Type: Quarterly Report - Quarterly Financials Q3 2017Filing Source: OTC Markets
Filing Date: November, 16 2017

 

 


Daily Technical Chart for (OTC: BSEM)

Daily Technical Chart for (OTC: BSEM)


Stay tuned for daily updates and more on (OTC: BSEM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BSEM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BSEM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BSEM and does not buy, sell, or trade any shares of BSEM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/